

BSE SENSEX **S&P CNX**
82,501 25,285



Stock Info

Bloomberg	BSE IN
Equity Shares (m)	406
M.Cap.(INRb)/(USD\$)	971.4 / 11
52-Week Range (INR)	3030 / 1226
1, 6, 12 Rel. Per (%)	4/16/69
12M Avg Val (INR M)	16030
Free float (%)	100.0

Financials Snapshot (INR b)

Y/E Mar	FY25	FY26E	FY27E
Net Sales	29.6	40.3	44.7
EBITDA	15.9	25.1	27.4
PAT	13.2	20.6	22.9
Adj PAT	13.2	20.5	22.9
EPS (INR)	32.4	50.8	56.3
EPS Gr (%)	213.5	56.7	10.8
BV / Sh (INR)	109	148	191

Ratios (%)

RoE	29.8	34.4	29.5
Payout ratio	23.6	23.3	23.3

Valuations


P/E (x)	73.5	46.9	42.4
P / BV (x)	21.9	16.1	12.5

Shareholding Pattern (%)

As On	Jun-25	Mar-25	Jun-24
Promoter	0.0	0.0	0.0
DII	11.3	12.3	11.6
FII	38.7	38.9	33.9
Others	50.0	48.8	54.5

FII includes depository receipts

Stock Performance (one-year)



CMP: INR2,385 TP: INR2,250 (-6%)

Neutral

Strong volume momentum; regulatory clouds persist

- The regulator is considering measures to increase the tenure of the options segment ([Link](#)). One of the measures could be shifting from weekly to monthly expiries for index contracts. If implemented, this could have significant impact on volumes for stock exchanges.
- Earlier, the regulatory mandate allowing only one weekly expiry per exchange (implemented in Nov'24) led to a shift in volumes from Bank Nifty to SENSEX, driving BSE's premium turnover market share up from 11.4% in Oct'24 to 24.4% in Sep'25. However, a large pool of FPIs is still in the process of setting up their systems following rack allocation, which is expected to further boost volumes.
- The shift of expiry from Tuesday to Thursday (implemented in Sep'25) brought fresh flows, increasing non-expiry day share to the mid-teens and expiry day share to 50-55%, albeit at the cost of a decline in Friday activity.
- Enhanced broker engagement and the combined order book initiative are driving improvements in execution quality and cash segment flows. BSE's bulk deals capacity has improved significantly (from 30-40% earlier to ~80-90%), while the infrastructure built for derivatives trading is also being leveraged to support cash activity.
- While recent momentum is encouraging, potential regulatory tightening of F&O products poses a key risk, contributing to a sharp correction in the stock price (trading at 37x FY27E P/E). According to our sensitivity analysis, the removal of weekly expiry could lead to a 35%/ 27% decline in our FY27 derivatives revenue/ PBT (revenue – regulatory fee – clearing cost), resulting in 21% impact on our FY27E EPS. Given the elevated regulatory risks, we reiterate our Neutral rating with a one-year TP of INR2,250 (based on 40x FY27E EPS).

Gaining market share amid several regulatory changes

- For BSE, many FPIs are yet to start trading in SENSEX. Institutions have rented colocation racks and are currently setting up their trading infrastructure, after which incremental participation is expected to continue in a phased manner.
- BSE's existing 340 colocation racks are fully occupied, with expansion to 500 racks expected by year-end as institutions await allocation. This growth is expected to enhance liquidity for BSE's products. Additionally, BSE has introduced charges on colocation trades, which will boost revenue going forward.
- The regulation permitting one weekly expiry product per exchange has caused volumes to shift from BANKNIFTY to SENSEX, leading BSE's premium turnover market share to rise from 11.4% in Oct'24 to 24.4% in Sep'25, while premium ADTO increased from INR90b in Oct'24 to INR157b in Sep'25.
- Following the shift in expiry from Tuesday to Thursday (effective 1st Sep'25), BSE witnessed increased trading both one day prior to expiry and in longer tenure contracts. This is reflected in the rise of BSE's non-expiry day market share from single digits to the mid-teens, which was offset by a decline in Friday volume market share.

Research Analyst: **Prayesh Jain** (Prayesh.Jain@MotilalOswal.com) / **Nitin Aggarwal** (Nitin.Aggarwal@MotilalOswal.com)

Research Analyst: **Kartikaya Mohata** (Kartikaya.Mohata@MotilalOswal.com) / **Muskan Chopra** (Muskan.Chopra@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Fact set and S&P Capital.

- BSE also witnessed incremental volumes from traders who maintained their existing strategy for Thursday expiry despite the shift. As a result, BSE's expiry day market share increased to 50-55% from ~50% prior to the change.
- BSE's market share in the clearing business has also improved, which is expected to further contribute to consolidated top-line growth going forward.

Future of derivatives segment remains uncertain

- Although various media reports have discussed the regulator's stance on weekly expiry, no formal regulatory consultation has been initiated.
- Weekly expiry products have witnessed strong adoption across the broader ecosystem of traders and hedgers; therefore, removing these contracts could negatively impact liquidity.
- While changing weekly expiry to fortnightly or monthly could improve margins, there is a risk of volume loss to Bank Nifty if the shift is made to monthly expiry.
- Alternatives to a complete ban on weekly expiry include implementing product suitability criteria or introducing additional guardrails to limit participation.
- BSE's current focus is on deepening existing offerings before launching new products. The exchange plans to relaunch Bankex, redesigned in line with SEBI's requirement for indices to be broad-based (minimum 15 stocks).
- Regarding the change in pricing structure, no regulatory approval is required. BSE currently charges ~10% lower transaction fees compared to NSE, providing headroom for potential price increases.
- According to our sensitivity analysis, assuming: 1) a 40% decline in notional turnover due to the removal of weekly expiry, and 2) an improvement in the premium-to-notional to 12bp, the derivatives segment revenue in FY27 is expected to decline 30% YoY, while segment profit (computed as revenue - regulatory fee - clearing cost) is expected to decline 25% YoY. The smaller decline in profit is due to clearing costs being linked to the number of contracts, while regulatory fees are tied to notional turnover. Compared to our current FY27 estimates, the derivatives segment revenue/profit would decline by 35%/27%.
- A smaller decline in notional turnover or improved premium-to-notional turnover could reduce the impact. Additionally, increasing the transaction fee is another lever to offset the effect.

Growing opportunities in the cash segment

- Stronger relationships with broker clients have driven higher order flows to BSE's platform, benefiting both the cash and derivatives segments. Several brokers have also begun active market-making on BSE, leading to more competitive order books and improved liquidity.
- The Star MF platform has boosted BSE's engagement with AMCs, facilitating stronger flows. Additionally, infrastructure established by HFTs for derivatives is being leveraged in the cash market, increasing liquidity and participation across both segments.
- In case of bulk deals, BSE can now provide 80-90% of the book (earlier 30-40%).
- In the top 100 stocks, many vendors now display combined order books by merging the best five bids from NSE and BSE, creating arbitrage opportunities for members. Analysis shows that BSE offered the best bid in ~25-30 of these

stocks. As a result, the exchange is educating institutional investors about this feature to enable the best price execution opportunities, contributing to an increase in smart order routing (SOR) from 1.7% in Apr'25 to 2.7% in Sep'25.

Valuation and view

- We expect BSE to sustain its market share gains and maintain robust volume traction, as witnessed in 1HFY26, supported by increasing member participation. Improved trajectory in the cash segment, robust demand for colocation, and strong positioning of the Star MF platform will also contribute to the company's performance.
- The stock has seen a sharp correction amid regulatory overhang related to potential F&O restrictions. The stock currently trades at 37x FY27E P/E. According to our sensitivity analysis, the removal of weekly expiry could lead to a 35%/ 27% decline in our FY27 derivatives revenue/ PBT (revenue – regulatory fee – clearing cost), resulting in 21% impact on our FY27E EPS. Given the elevated regulatory risks, we reiterate our Neutral rating with a one-year TP of INR2,250 (based on 40x FY27E EPS).

Exhibit 1: Sensitivity analysis for weekly expiry removal impact - derivative revenue


FY27E Revenue (INR m)		Notional turnover YoY growth				
		-20%	-30%	-40%	-50%	-60%
Premium/ notional ratio	0.10%	19,371	16,949	14,528	12,107	9,685
	0.12%	23,245	20,339	17,433	14,528	11,622
	0.14%	27,119	23,729	20,339	16,949	13,559
	0.16%	30,993	27,119	23,245	19,371	15,496
	0.18%	34,867	30,509	26,150	21,792	17,433
	0.20%	38,741	33,898	29,056	24,213	19,371

Source: MOFSL


Exhibit 2: Sensitivity analysis for weekly expiry removal impact - derivative PBT

FY27E PBT (INR m)		Notional turnover YoY growth				
		-20%	-30%	-40%	-50%	-60%
Premium/ notional ratio	0.10%	13,774	12,053	10,331	8,609	6,887
	0.12%	17,649	15,442	13,236	11,030	8,824
	0.14%	21,523	18,832	16,142	13,452	10,761
	0.16%	25,397	22,222	19,048	15,873	12,698
	0.18%	29,271	25,612	21,953	18,294	14,635
	0.20%	33,145	29,002	24,859	20,716	16,572

Source: MOFSL. Note: Derivative PBT is calculated as revenue - regulatory fee - clearing cost)

Exhibit 3: Scenario analysis for BSE's derivative revenue in FY27


Source: MOFSL

Exhibit 4: Scenario analysis for BSE's derivative PBT in FY27



Source: MOFSL. Note: Derivative PBT is calculated as revenue - regulatory fee - clearing cost)

Exhibit 5: BSE's premium turnover market share has improved on expiry and non-expiry days

BSE's option premium market share (%)	Mon	Tue	Wed	Thu	Fri
28 Jul - 1Aug'25	29.1	45.4	9.6	7.9	27.0
4-8 Aug'25	33.0	47.9	11.5	10.1	28.1
10-15 Aug'25	33.1	51.1	12.3	10.0	0.0
18-22 Aug'25	31.5	50.4	10.7	8.8	25.3
25-29 Aug'25	30.6	45.2	NA	7.0	17.7
1- 5 Sep'25 (Shift in expiry)	14.9	11.2	39.2	52.3	14.7
8-12 Sep'25	14.3	11.4	35.0	49.9	13.2
15-19 Sep'25	14.1	12.0	33.1	48.1	13.5
22-26 Sep'25	14.6	11.9	36.7	49.7	12.5
29 Sep - 03 Oct'25	12.8	10.4	49.9	NA	15.0


Source: BSE, NSE, MOFSL

Exhibit 6: BSE's premium ADTO on a rising trajectory




Source: Company, MOFSL

Exhibit 7: Increasing member count in derivatives along with rising UCCs




Source: MOFSL, Company

Exhibit 8: Significant contribution by individuals to derivative volumes (%)




Source: MOFSL, Company

Exhibit 9: Cash market share improving but remains low




Source: MOFSL, Company

Exhibit 10: Member count has significantly increased in cash




Source: MOFSL, Company

Exhibit 11: Revenue growth momentum to decline...




Source: MOFSL, Company

Exhibit 12: ...driven by growth stabilizing in derivatives




Source: MOFSL, Company

Exhibit 13: EBITDA margin likely to remain stable at 60%+




Source: MOFSL, Company

Exhibit 14: PAT growth to remain consistent



Source: MOFSL, Company

Exhibit 15: Significant correction in the stock recently due to regulatory uncertainty



Source: MOFSL, Company

Financials and valuations

Income Statement								(INR m)
Y/E March	2021	2022	2023	2024	2025	2026E	2027E	2028E
Revenue	5,014	7,432	8,155	13,901	29,573	40,260	44,653	50,908
Change (%)	11.3	48.2	9.7	70.5	112.7	36.1	10.9	14.0
Employee expenses	1,487	1,773	1,802	1,991	2,366	2,887	3,319	3,817
Technology expenses	948	969	1,239	1,374	1,643	2,054	2,362	2,716
Admin & Others	1,792	1,918	2,227	5,591	9,668	10,238	11,595	13,138
Liquidity enhancement expenses	337	350	363	0	0	0	0	0
EBITDA	450	2,422	2,524	4,945	15,896	25,082	27,377	31,236
EBITDA %	9.0	32.6	30.9	35.6	53.8	62.3	61.3	61.4
Depreciation / Amortization	579	483	603	949	1,130	1,142	1,298	1,454
EBIT	-128	1,939	1,920	3,996	14,766	23,940	26,079	29,783
EBIT %	-2.6	26.1	23.5	28.7	49.9	59.5	58.4	58.5
Finance costs	103	222	275	0	0	0	0	0
Other Income	1,533	1,204	1,384	2,248	2,790	3,308	4,165	5,017
SGF	62	291	550	917	900	900	1,200	1,200
PBT	1,240	2,631	2,480	5,327	16,656	26,348	29,044	33,600
Tax	109	823	916	1,844	4,312	6,693	7,261	8,400
ETR %	8.8	31.3	36.9	34.6	25.9	25.4	25.0	25.0
PAT before associate profits	1,131	1,808	1,564	3,483	12,344	19,656	21,783	25,200
Share of Associates profit	432	642	492	718	826	867	1,084	1,355
PAT after Associate profits	1,562	2,449	2,056	4,201	13,170	20,523	22,867	26,555
Change (%)	76.4	56.8	-16.0	104.3	213.5	55.8	11.4	16.1
PAT margin %	31.2	33.0	25.2	30.2	44.5	51.0	51.2	52.2
Exceptional items	-145	0	0	3,675	0	120	0	0
PAT after exceptional items	1,417	2,449	2,056	7,876	13,170	20,643	22,867	26,555

Balance Sheet								(INR m)
Y/E March	2021	2022	2023	2024	2025	2026E	2027E	2028E
Total fixed assets	1,843	1,681	2,535	2,991	3,540	4,040	4,540	5,040
Non current investments	8,005	6,298	8,961	11,529	13,247	13,909	14,604	15,334
Other non current assets	4,914	4,339	9,871	20,283	13,203	13,467	13,737	14,011
Total non current assets	14,762	12,318	21,367	34,803	29,990	31,416	32,881	34,386
Cash & Current investments	19,269	35,117	30,496	44,629	51,839	67,423	86,839	1,09,192
Trade receivables	876	634	909	2,109	3,097	6,442	7,145	8,145
Other current assets	11,364	13,785	7,166	12,962	18,491	19,317	20,183	21,089
Total current assets	31,509	49,535	38,571	59,699	73,427	93,182	1,14,166	1,38,426
TOTAL ASSETS	46,271	61,854	59,938	94,502	1,03,417	1,24,599	1,47,047	1,72,812
Share Capital	270	271	271	271	271	812	812	812
R&S	24,796	26,275	26,741	32,752	43,967	59,252	76,783	97,142
Shareholders equity	25,066	26,545	27,012	33,023	44,237	60,064	77,595	97,954
Core SGF	5,391	6,409	7,576	9,550	11,326	11,326	11,326	11,326
Minority Interest	235	1,352	1,278	1,524	1,520	1,520	1,520	1,520
Other LT liabilities	124	109	145	136	187	187	187	187
Total non-current liabilities	124	109	145	136	187	187	187	187
Outstanding dues to creditors	982	729	804	3,603	1,140	2,298	2,612	2,972
Other current liabilities	14,473	26,711	23,123	46,667	45,007	49,204	53,807	58,854
Total current liabilities	15,455	27,439	23,927	50,270	46,146	51,502	56,419	61,825
TOTAL LIABILITIES	46,271	61,854	59,938	94,502	1,03,417	1,24,599	1,47,047	1,72,812

Financials and valuations

Cash Flow								(INR m)
Y/E March	2021	2022	2023	2024	2025	2026E	2027E	2028E
PAT	1,417	2,449	2,056	7,876	13,170	20,643	22,867	26,555
Dep	579	483	603	949	1,130	1,142	1,298	1,454
Changes in working capital	83	2,131	-7,305	12,727	-2,476	(296)	1,703	1,670
Op Cash flow	2,079	5,063	(4,645)	21,551	11,824	21,489	25,868	29,678
Capex	(337)	(321)	(1,457)	(1,405)	(1,672)	(1,642)	(1,798)	(1,954)
Investments	2,882	(1,240)	5,171	(9,364)	(4,549)	(1,423)	(1,494)	(1,569)
Investing cash flow	2,545	(1,561)	3,713	(10,769)	(6,221)	(3,064)	(3,291)	(3,522)
Changes in equity	218	999	34	166	1,158	-	0	-
Debt	(1,932)	11,181	(3,193)	2,996	1,798	1,977	2,175	2,393
Dividend	(962)	(1,827)	(1,624)	(2,030)	(3,113)	(4,817)	(5,336)	(6,196)
Financing cash flow	(2,676)	10,353	(4,783)	1,132	(158)	(2,839)	(3,161)	(3,804)
Cash generation	1,948	13,855	(5,715)	11,914	5,445	15,585	19,415	22,353
Op Cash	16,092	19,269	35,117	30,496	44,629	51,839	67,423	86,839
CI Cash	19,269	35,117	30,496	44,629	51,839	67,423	86,839	1,09,192

Ratios								
Y/E March	2021	2022	2023	2024	2025	2026E	2027E	2028E
Basic (INR)								
EPS	3.5	6.0	5.1	19.4	32.4	50.8	56.3	65.4
EPS (excl EOI)	3.8	6.0	5.1	10.3	32.4	50.5	56.3	65.4
Cash EPS	3.8	6.3	5.4	20.0	33.1	51.5	57.1	66.3
Book Value	61.7	65.4	66.5	81.3	108.9	147.9	191.1	241.2
DPS	2.4	4.5	4.0	5.0	7.7	11.9	13.1	15.3
Payout %	22.6	24.9	26.3	25.8	23.6	23.3	23.3	23.3
Valuation (x)								
P/E	619.9	395.4	471.0	230.5	73.5	47.2	42.4	36.5
Cash P/E	620.1	376.8	438.8	119.4	72.0	46.3	41.8	36.0
Price/Book Value	38.6	36.5	35.9	29.3	21.9	16.1	12.5	9.9
Dividend Yield (%)	0.1	0.2	0.2	0.2	0.3	0.5	0.6	0.6
Profitability Ratios (%)								
RoE	5.7	9.2	7.6	23.8	29.8	34.4	29.5	27.1
RoCE	5.6	11.8	12.2	18.9	39.7	45.4	39.0	35.5
RoIC	2.4	2.4	1.6	7.2	26.0	30.1	25.5	23.2

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act") and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).

6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.